ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
December 10, 2024Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax , in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis.
Pharma Sources Insight January 2025
